Background
Methods
Patients
PCR direct sequencing of the JAK2 locus
Allele-specific PCR analysis
Genotyping
Statistical analysis
Results
Minor allele frequency of SNPs from the JAK2 locus in Japanese PV patients
No. | SNP | Minor alleles in PV (n= 28) | Minor alleles in control (n= 28) |
Pvalue* (Chi square test) | Odds ratio (95% CI) | ||||
---|---|---|---|---|---|---|---|---|---|
No | Yes (homo/hetero) | % | No | Yes (homo/hetero) | % | ||||
1 | rs10974944 (c→g) | 7 | 21 (15/6) | 75 | 17 | 11 (3/8) | 39.2 | 0.0069 | 4.64 (1.49-14.55) |
12 | rs12686652 (c→g) | 6 | 22 (21/1) | 78.6 | 14 | 14 (5/9) | 50 | 0.0257 | 3.67 (1.14-11.79) |
13 | rs12335546(c→t) | 6 | 22 (21/1) | 78.6 | 19 | 9 (1/8) | 32.1 | 0.0005 | 7.74 (2.33-25.75) |
19 | rs4495487 (t→c) | 7 | 21 (21/0) | 75 | 23 | 5 (3/2) | 17.8 | < 0.0001 | 13.8 (3.79-50.21) |
22 | rs1028730 (g→a) | 6 | 22 (21/1) | 78.5 | 19 | 9 (2/7) | 32.1 | 0.0005 | 7.74 (2.33-25.75) |
24 | rs12343867(t→c) | 7 | 21 (21/0) | 75 | 17 | 11 (4/9) | 39.3 | 0.0069 | 4.64 (1.48-14.55) |
JAK2 SNP distribution in MPN patients and controls
Case population | Control population | SNP |
P
| Genotype¶
| Odds ratio (95% CI) | |||
---|---|---|---|---|---|---|---|---|
Major | Hetero | Homo | Major vs Hetero | Major vs Homo | ||||
JAK2 V617F-positive PV | Healthy volunteers | rs10974944 | 0.0126* | CC | CG | GG | 2.75 (1.06-7.14)* | 4.24 (1.51-11.92)* |
(n = 33) | Japanese (n = 107) | rs4495487 | < 0.0001* | TT | TC | CC | 4.26 (1.56-11.61)* | 11.31 (3.60-35.57)* |
rs12343867 | 0.0032* | TT | TC | CC | 2.26 (0.88-5.77) | 5.683 (1.98-16.35)* | ||
JAK2 V617F-positive ET | Healthy volunteers | rs10974944 | 0.0371* | CC | CG | GG | 2.42 (1.20-4.92)* | 1.10 (0.40-3.02) |
(n = 57) | Japanese (n = 107) | rs4495487 | 0.0009* | TT | TC | CC | 3.97 (1.86-8.49)* | 4.00 (1.44-11.14)* |
rs12343867 | 0.0013* | TT | TC | CC | 3.52 (1.68-7.38)* | 3.55 (1.33-9.52)* | ||
JAK2 V617F-negative ET | Healthy volunteers | rs10974944 | 0.068 | CC | CG | GG | 2.58 (1.14-5.84)* | 1.49 (0.50-4.46) |
(n = 39) | Japanese (n = 107) | rs4495487 | 0.0097* | TT | TC | CC | 3.28 (1.45-7.43)* | 3.05 (0.95-9.58) |
rs12343867 | 0.112 | TT | TC | CC | 2.26 (1.01-5.04)* | 2.08 (0.67-6.40) | ||
JAK2 V617F-positive MPN | Healthy volunteers | rs10974944 | 0.0138* | CC | CG | GG | 2.42 (1.29-4.55)* | 2.24 (1.03-4.88)* |
(PV, ET, and PMF, n = 95) | Japanese (n = 107) | rs4495487 | < 0.0001* | TT | TC | CC | 4.08 (2.13-7.84)* | 6.88 (2.88-16.41)* |
rs12343867 | 0.0002* | TT | TC | CC | 2.89 (1.53-5.45)* | 5.54 (2.35-13.06)* | ||
JAK2 V617F-negative MPN | Healthy volunteers | rs10974944 | 0.1961 | CC | CG | GG | 2.01 (0.92-4.37) | 1.14 (0.39-3.37) |
(PV, ET, and PMF, n = 43) | Japanese (n = 107) | rs4495487 | 0.024* | TT | TC | CC | 2.79 (1.28-6.08)* | 2.48 (0.78-7.80) |
rs12343867 | 0.3069 | TT | TC | CC | 1.78 (0.82-3.84) | 1.63 (0.58-4.94) | ||
JAK2 V617F-positive MPN | JAK2 V617F-negative MPN | rs10974944 | 0.5493 | CC | CG | GG | 1.21 (0.55-2.66) | 1.82 (0.70-5.35) |
(PV, ET, and PMF, n = 95) | (PV, ET and PMF, n = 43) | rs4495487 | 0.1762 | TT | TC | CC | 1.46 (0.66-3.31) | 2.78 (0.93-6.29) |
rs12343867 | 0.1572 | TT | TC | CC | 1.62 (0.72-3.61) | 2.71 (0.93-7.90) |
GCC genotype | non-GCC genotype |
P(Chi-square test) | Odds ratio | 95% CI | |
---|---|---|---|---|---|
Case Population | 46/1 haplotype rs4495987(+) | non-46/1 haplotype rs4495987(-) | |||
JAK2V617F-positive PV (n = 33) | 22 | 11 | 0.0023 | 3.63 | 1.59-8.29 |
JAK2V617F-positive ET (n = 57) | 35 | 22 | 0.0043 | 2.72 | 1.40-5.32 |
JAK2V617F-negative ET (n = 39) | 24 | 15 | 0.0076 | 2.91 | 1.36-6.19 |
JAK2V617F-positive MPN (n = 95) | 60 | 35 | 0.0001 | 3.07 | 1.73-5.46 |
JAK2V617F-negative MPN (n = 43) | 24 | 19 | 0.0289 | 2.26 | 1.01-4.70 |
Control: non-MPN (n = 107) | 38 | 69 |
Category | Genotype |
JAK2V617F allele burden |
Pvalue | |||
---|---|---|---|---|---|---|
negative | < 20% | 20-80% | > 80% | |||
PV | GCC (-) | 0 | 0 | 7 | 3 | |
GCC (+) | 0 | 0 | 18 | 5 | ||
ET | GCC (-) | 17 | 8 | 14 | 1 | 0.4198 |
GCC (+) | 22 | 14 | 15 | 5 | ||
PMF | GCC (-) | 4 | 1 | 1 | 0 | |
GCC (+) | 0 | 0 | 2 | 1 | ||
MPN | GCC (-) | 21 | 8 | 22 | 4 | 0.6815 |
GCC (+) | 22 | 15 | 36 | 10 |
Clinical and hematological features, JAK2 V617F, and the GCC genotype
JAK2V617F negative | JAK2 V617F positive | ||||
---|---|---|---|---|---|
GCC genotype | GCC genotype |
Pvalue | |||
No ( n = 19) | Yes ( n = 23) | No ( n = 22) | Yes ( n = 35) | ||
Age, mean (SD) | 51.2 (18.3) | 57.9 (17.5) | 64.8 (14.9) | 66.1 (16.2) | 0.6466 |
Sex | |||||
Female | 10 (52.6%) | 14 (60.9%) | 8 (36.4%) | 22 (62.9%) | 0.2965 |
Male | 9 (47.4%) | 9 (30.1%) | 14 (64.6%) | 13 (37.1%) | |
Splenomegaly | 11/16 (68.8%) | 4/22 (18.2%) | 5/20 (25%) | 4/33 (12.1%) | 0.0448* |
Thrombosis | 0/11 (0%) | 5/21 (23.8%) | 6/17 (35.3%) | 7/30 (23.3%) | 0.0446* |
Therapy requirement | 10/16 (90%) | 15/22 (68.2%) | 7/21 (33.3%) | 25/34 (73.5%) | 0.7408 |
Cytogenetic abnormality | 1/8(0%) | 0/16 (0%) | 2/9 (22.2%) | 4/21(19%) | 0.3618 |
MF evolution | 0/16 (0%) | 1/22 (4.5%) | 0/15 (0%) | 1/30 (3.3%) | 0.3787 |
AML evolution | 0/11 (0%) | 1/22 (4.5%) | 0/15 (0%) | 0/30 (0%) | 0.7343 |
Survival, mean (SD) | 2036 (2267) | 1883 (1643) | 1706 (1847) | 1717 (292) | 0.6528 |
GCC genotype | |||
---|---|---|---|
No (n= 10) | Yes (n= 23) |
Pvalue | |
Age, mean (SD) | 63.2 (12.4) | 60.7 (14.0) | 0.5779 |
Sex | |||
Female | 4 (40%) | 13 (56.7%) | 0.4646 |
Male | 6 (60%) | 10 (43.5%) | |
Splenomegaly | 5/10 (50%) | 12/23 (52.2%) | 0.7413 |
Thrombosis | 3/10 (30%) | 4/20 (20%) | 0.4786 |
Therapy requirement | 9/10 (90%) | 22/23 (95.7%) | 0.2585 |
Cytogenetic abnormality | 0/10 (0%) | 3/23 (13%) | 0.1781 |
MF evolution | 3/10 (30%) | 3/23 (13%) | 0.0924 |
AML evolution | 1/10 (10%) | 3/23 (13%) | 0.7614 |
Survival, median (SD) | 3427 (2336) | 2840 (2822) | 0.7583 |